Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Mol Cancer Ther (2025) 24 (4): 511–522. Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are ...

“A standard approach for patients with metastatic prostate cancer has been to give drugs that target the androgen receptor, and then if that fails, to give chemotherapy,” Dr. Morris explains. “But ...

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor ...